newsfilter
← Latest News
GlobeNewswire·

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. ("Arch" or the "Company") (TSXV:ARCH, OTCQB:ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA")